Questcor Pharmaceuticals Inc

Questcor Pharmaceuticals — Q3 2013 Earnings Presentation

17 slides from Questcor Pharmaceuticals's earnings presentation, Nov 4, 2013

  1. Slide 1: Third Quarter 2013 Conference Call

    Third Quarter 2013 Conference Call NASDAQ: QCOR Exhibit 99.3 Third Quarter 2013 Conference Call NASDAQ: QCOR

  2. Slide 2: Conference Call Logistics

    2 • Today’s webcast, accompanying slide presentation and archived replay is available online at • Telephone replay is available by dialing: – U.S.: (855) 859-2056. – International: (404) 537-3406. – Passcode: 76004546 Conference Call Logistics http://ir.questcor.com/events.cfm • Today’s webcast, acc

  3. Slide 3: Safe Harbor Statement

    3 Safe Harbor Statement Note: Except for the historical information contained herein, this press release contains forward-looking statements that have been made pursuant to the Private Securities Litigation Reform Act of 1995. These statements relate to future events or our future financial performa

  4. Slide 4: Q3-2013 Financial Highlights

    4 • 8,132 vials shipped, up 45% YOY • $236.3M net sales, up 68% YOY • $1.52 GAAP diluted EPS, up 67% YOY • $1.68 Non-GAAP diluted EPS, up 73% YOY • $17.1M R&D investment, up 114% YOY Q3-2013 Financial Highlights • 8,132 vials shipped, up 45% YOY • $236.3M net sales, up 68% YOY • $1.52 GAAP diluted E

  5. Slide 5: Paid Rx Comparison: New Paid Acthar Prescriptions by Therapeutic Area

    5 Paid Rx Comparison New Paid Acthar Prescriptions by Therapeutic Area* Based on internal company estimates. Q3 – 2013 Q3 – 2012 Q2 – 2013 NS 370 - 7% 7% MS 1,370 - 1,400 4% 8% IS 225 - 33% 7% Rheumatology 450 - N/M 43% Total 2,450 - 2,500 ** 30% 10% * Includes prescriptions covered by commercial ca

  6. Slide 6: Acthar Business Diversification Continues

    6 Acthar Business Diversification Continues Based on internal company estimates. Based on Acthar Net Sales

  7. Slide 7: R&D Objective: Addressing Unmet Medical Needs with Acthar and Synacthen

    7 • Understanding the biological properties of melanocortin peptides such as Acthar and Synacthen – Specific biochemical pathways, cells, and tissues – Immunomodulation and anti-inflammatory effects • Understanding the benefit of Acthar in devastating medical conditions • Building the body of eviden

  8. Slide 8: Company-Sponsored Acthar Clinical Trials

    8 Pre-Clinical Phase 1 Phase 2 Phase 3 Phase 4 Company-Sponsored Acthar Clinical Trials IDIOPATHIC MEMBRANOUS NEPHROPATHY SYSTEMIC LUPUS ERYTHEMATOSUS DIABETIC NEPHROPATHY AMYOTROPHIC LATERAL SCLEROSIS ACUTE RESPIRATORY DISTRESS SYNDROME

  9. Slide 9: ALS Phase Open-Label Safety Study for Acthar

    9 ALS Phase 2 Open-Label Safety Study for Acthar • Goals – Assess short-term safety and tolerability of Acthar in ALS – Inform dosage selection for future studies • Study Design – Enroll up to 40 patients at multiple sites in U.S. – 8-week treatment, plus optional 28-week open label extension – Pati

  10. Slide 10: ARDS Phase Safety and Efficacy Study for Acthar

    10 ARDS Phase 2 Safety and Efficacy Study for Acthar • Goals – Determine if Acthar increases number of ventilator-free days during 28-day treatment period – Assess if Acthar reduces mortality, organ failure, length of hospital or ICU stay – Inform dosage selection for future studies • Study Design –

  11. Slide 11: Q3-2013 Financial Results

    11 Q3-2013 Financial Results Q3 – 2013 Q3 – 2012 Change Net Sales ($M) $236.3 $140.3 68% Fully Diluted, GAAP EPS $1.52 $0.91 67% Fully Diluted, Non-GAAP EPS $1.68 $0.97 73% Cash and short term investments ($M) $281.1 * $111.9 Cash flow from operations ($M) $108.9 $51.2 Diluted shares outstanding 62.

  12. Slide 12: Reconciliation of Non-GAAP Adjusted Financial Disclosure

    12 Reconciliation of Non-GAAP Adjusted Financial Disclosure Reconciliation of Non-GAAP Adjusted Financial Disclosure Three Months Ended Nine Months Ended September 30, September 30, 2013 2012 2013 2012 Adjusted net income $104,368 $59,427 $233,328 $143,943 Share-based compensation expense (1) (5,269

  13. Slide 13: Q3-2013 Financial Highlights

    13 • 8,132 vials shipped, up 45% YOY • $236.3M net sales, up 68% YOY • $1.52 GAAP diluted EPS, up 67% YOY • $1.68 Non-GAAP diluted EPS, up 73% YOY • $17.1M R&D investment, up 114% YOY Q3-2013 Financial Highlights • 8,132 vials shipped, up 45% YOY • $236.3M net sales, up 68% YOY • $1.52 GAAP diluted

  14. Slide 14: 3-Year Net Sales Growth: Annualized Quarterly Net Sales

    14 3-Year Net Sales Growth Annualized Quarterly Net Sales ($M) Each bar represents the applicable third quarter net sales multiplied by 4.

  15. Slide 15: 3-Year Net Sales Growth: Quarterly Net Sales

    15 3-Year Net Sales Growth Quarterly Net Sales ($M)

  16. Slide 16: A Strong Foundation for Growth

    16 • Increased penetration of current Acthar markets – Lupus, RA are new Acthar markets in very early development • Pilot selling effort beginning soon in pulmonology for on-label symptomatic sarcoidosis indication – Possible Acthar role in current dermatology and ophthalmology indications also curr

  17. Slide 17: Third Quarter 2013 Conference Call

    Third Quarter 2013 Conference Call NASDAQ: QCOR Third Quarter 2013 Conference Call NASDAQ: QCOR

Questcor Pharmaceuticals — Q3 2013 Earnings Presentation on 6ix